Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

agulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  MedSpring Urgent Care, an ... clinic at 517 S. Lamar Blvd., Austin, TX ... clinic is located on the southeast corner of Barton Springs ... from 9 a.m. - 9 p.m. daily, including weekends and holidays. ... Texas, Central Austin , Anderson Mill , ...
(Date:7/28/2014)... 28, 2014  TNI BioTech, Inc. (OTCQB: TNIB) ... on the development, marketing and distribution of opioid-related ... proxy materials with the Securities and Exchange Commission ... Shareholders to be held on Thursday, September 4, ... record date for determining those shareholders eligible to ...
(Date:7/28/2014)... BEIJING , July 28, 2014 Concord ... (NYSE: CCM ), a leading specialty hospital ... of radiotherapy and diagnostic imaging centers in ... 2014, its Board of Directors declared a special cash ... American Depositary Share ("ADS")) on the Company,s outstanding ordinary ...
Breaking Medicine Technology:MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2
... The Iowa Health Information Technology Regional Extension Center (HITREC) has selected ... record (EHR), practice management and interoperability solution PrimeSuite® , as ... federal Department of Health and Human Services (HHS) REC healthcare ... , ...
... PRINCETON, N.J. , July 12 ... Co., Ltd., has launched AFC Medirepair® with Signum,s ... .  Arazine™ is the first compound from Signum,s ... pipeline of Signal Transduction Modulators (STMs). The DRx ...
Cached Medicine Technology:Iowa Regional Extension Center Selects Greenway EHR Solutions 2Iowa Regional Extension Center Selects Greenway EHR Solutions 3Iowa Regional Extension Center Selects Greenway EHR Solutions 4Iowa Regional Extension Center Selects Greenway EHR Solutions 5Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 2Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 3
(Date:7/28/2014)... (July 28, 2014) -- Researchers from The University of Texas ... and other institutions have identified a combination of pills that ... of the drugs sofosbuvir and simeprevir, with or without ribavirin, ... well tolerated by patients, according to the study published today ... conducted in the U.S. , Eric Lawitz, M.D., clinical ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... The Oneida Indian Nation today announced that golf ... PGA TOUR players will be teeing up with four-time ... for the seventh annual Notah Begay III Foundation (NB3F) ... Atunyote® Golf Club on Wednesday, August 27, the star-studded ... Walker, Jonas Blixt, Angel Cabrera and Louis Oosthuizen, in ...
(Date:7/28/2014)... San Jose, CA (PRWEB) July 28, 2014 ... and family life Americans face today, BlogHer, The Center ... up to launch “Make Life Work,” a campaign to ... faced by families across the U.S. The joint initiative ... by Stacy Morrison, Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, ...
(Date:7/28/2014)... 28, 2014 According to a ... Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology (CVD, ... (Power, Opto-electronic), Application, and Geography-2013-2020", published by MarketsandMarkets, ... CAGR of 12.63% from 2014 to 2020 and ... market data tables and 88 figures spread through ...
Breaking Medicine News(10 mins):Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 2Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 3Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 4
... In a case study that illustrates the need for people ... themselves from pets, a woman with numbness in her feet caused ... Jack Russell terrier chewed off part of her slightly infected big ... the Journal of the American Podiatric Medical Association . ...
... -- The drug telaprevir (Incivek) provides a dramatic improvement in ... infection, says an international team of investigators led by Dr. ... Their study, published in today,s edition of the New ... agent for patient use by the U.S. Food and Drug ...
... HealthDay Reporter , WEDNESDAY, June 22 (HealthDay News) -- Silicone-gel ... of women with the devices requiring removal within 10 years ... And "the longer a woman has the implants, the more ... for the Center for Devices and Radiological Health at the ...
... Medical Center (GUMC) have defined, for the first time, three ... sounds such as speech and discovered that they are ... the June 22 issue of the Journal of Neuroscience ... the help of 13 human volunteers who spent time in ...
... , WEDNESDAY, June 22 (HealthDay News) -- Although depression ... giving birth, those who have had an eating disorder or ... the condition, according to a new study. This ... routine part of prenatal care, concluded researchers from the University ...
... WEDNESDAY, June 22 (HealthDay News) -- People who are born ... anxiety and mood disorders due to the impact that city ... emotion and stress, a new international study indicates. The ... of life for city dwellers, according to the researchers. ...
Cached Medicine News:Health News:Cautionary tale for people with diabetes: Dog consumed part of a sleeping patient's toe 2Health News:NEJM study: New drug represents breakthrough in treatment of hepatitis C 2Health News:NEJM study: New drug represents breakthrough in treatment of hepatitis C 3Health News:FDA: Breast Implants Basically Safe, But Won't Last a Lifetime 2Health News:FDA: Breast Implants Basically Safe, But Won't Last a Lifetime 3Health News:Researchers identify components of speech recognition pathway in humans 2Health News:Researchers identify components of speech recognition pathway in humans 3Health News:Eating Disorders May Raise Risk of Depression in Pregnancy 2Health News:City Living Tied to More Anxiety, Mood Disorders 2
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
... an immunochromatography based one step in vitro ... Opiates and its metabolite in human urine,specimens. ... above a cut-off level of 300 ng/mL,can ... evaluated in the point of care location ...
... test is an immunochromatography based one ... for qualitative determination of Methamphetamine in ... of 1000 ng/mL. This assay has ... of care,location and is for use ...
Medicine Products: